evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,815 questions · 6,211 findings · 638 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,052 · 16.9%GRADE not reported 441 · 7.1%Very low 1,700 · 27.4%Low 1,651 · 26.6%Moderate 1,070 · 17.2%High 297 · 4.8%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings: Fibrin sealant vs usual care

Risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) · people aged 18 and over undergoing vascular surgery

It is very uncertain whether summary of findings: Fibrin sealant changes risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) compared with usual care (very low certainty).

1 finding from 1 review

Tranexamic acid vs placebo

Risk of receiving any allogeneic blood product (data only available for intraoperative blood product use) · people aged 18 and over undergoing vascular surgery

It is very uncertain whether summary of findings: Tranexamic acid changes risk of receiving any allogeneic blood product (data only available… compared with placebo (very low certainty).

1 finding from 1 review

Tranexamic acid vs placebo

Risk of reoperation or repeat procedure for bleeding within 7 days · people aged 18 and over undergoing vascular surgery

It is very uncertain whether summary of findings: Tranexamic acid changes risk of reoperation or repeat procedure for bleeding within 7 days compared with placebo (very low certainty).

1 finding from 1 review

Tranexamic acid vs placebo

Risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) · people aged 18 and over undergoing vascular surgery

Summary of findings: Tranexamic acid showed no clear difference in risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) compared with placebo (low certainty).

1 finding from 1 review

Summary of findings: Fibrin sealant vs usual care

All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery

It is very uncertain whether summary of findings: Fibrin sealant changes all‐cause mortality up to 30 days compared with usual care (very low certainty).

1 finding from 1 review

Summary of findings: Fibrin sealant vs usual care

Risk of reoperation or repeat procedure for bleeding within 7 days · people aged 18 and over undergoing vascular surgery

It is very uncertain whether summary of findings: Fibrin sealant changes risk of reoperation or repeat procedure for bleeding within 7 days compared with usual care (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

It is very uncertain whether summary of findings table ‐ Oral classical immunosuppressants… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in short‐term hair regrowth ≥ 75% compared with placebo (low certainty).

1 finding from 1 review

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Oral small molecule inhibitors… leads to higher short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (high certainty).

1 finding from 1 review

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Incidence of serious adverse events · adults with alopecia areata

Summary of findings table ‐ Oral small molecule inhibitors… showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).

1 finding from 1 review